Flomax
Product Images NDC 67296-1803

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Flomax (NDC 67296-1803). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Epm 30 Count (67296 1803 3)

Label for FLOMAX 0.4 mg capsules, containing 30 capsules. The label shows NDC 67296-1803-3 and indicates the product is Rx only. Manufacturer is Sanofi-Aventis U.S. LLC, Bridgewater, NJ. Distributed by RedPharm Drug, Eden Prairie, MN. The label includes storage instructions at 20-25°C (68-77°F) and package insert reference for dosage.*

FDA Label Image

Chemical Structure (Flomax 01)

Chemical structure diagram of the active ingredient in FLOMAX, showing molecular components and bonds, including the hydrochloride (HCl) salt form.*

FDA Label Image

Figure 1 (Flomax 02)

A line graph depicting plasma concentration (ng/mL) over time (hours) comparing two conditions: fasted (dashed line) and fed (solid line). The graph shows concentration levels rising and declining for both conditions over a 36-hour period.*

FDA Label Image

Figure 2a (Flomax 03)

A line graph depicting mean change over treatment duration (weeks) for FLOMAX comparing two dosages, 0.8 mg and 0.4 mg, versus placebo. The x-axis represents treatment duration in weeks from 0 to 13, and the y-axis shows mean change, ranging from 0 to -11. The data points and lines illustrate that the 0.8 mg dose shows the greatest mean decrease, followed by 0.4 mg, with placebo showing the least change.*

FDA Label Image

Figure 2b (Flomax 04)

A line graph showing mean change in a measured outcome over 13 weeks of treatment comparing FLOMAX 0.8 mg, 0.4 mg, and placebo. The x-axis represents duration of treatment in weeks, and the y-axis represents mean change. The graph includes sample sizes (n) at various time points and indicates FLUXMAX doses compared to placebo across time.*

FDA Label Image

Figure 3a (Flomax 05)

A line graph showing the mean change in a variable measured in mL/sec over a 13-week treatment period, followed by a LOCF timepoint. The graph compares three groups: Treatment with 0.8 mg, Treatment with 0.4 mg, and Placebo. The mean change increases quickly for the treatment groups early on and then stabilizes, while the placebo group shows a lower and more gradual increase. Sample sizes for each time point are noted along the x-axis.*

FDA Label Image

Figure 3b (Flomax 06)

A line graph showing mean change in mL/sec over duration of treatment in weeks for FLOMAX at two dosages (0.8 mg and 0.4 mg) compared to placebo. The graph plots mean change on the vertical axis against treatment duration on the horizontal axis, illustrating higher mean changes for both FLOMAX dosages compared to placebo throughout the study.*

FDA Label Image

Principal Display Panel (0.4 mg Capsule Bottle Label)

Packaging label for Flomax 0.4 mg capsules containing tamsulosin hydrochloride. The label indicates a package of 100 capsules, prescription only, distributed by Sanofi. It includes storage instructions, barcode, and manufacturing details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.